GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » Piotroski F-Score

DexCom (DexCom) Piotroski F-Score

: 7 (As of Today)
View and export this data going back to 2005. Start your Free Trial

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

DexCom has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for DexCom's Piotroski F-Score or its related term are showing as below:

DXCM' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 7
Current: 7

During the past 13 years, the highest Piotroski F-Score of DexCom was 7. The lowest was 3. And the median was 5.


DexCom Piotroski F-Score Historical Data

The historical data trend for DexCom's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 6.00 5.00 7.00 7.00

DexCom Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 6.00 5.00 5.00 7.00

Competitive Comparison

For the Medical Devices subindustry, DexCom's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexCom Piotroski F-Score Distribution

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where DexCom's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 48.6 + 115.9 + 120.7 + 256.3 = $542 Mil.
Cash Flow from Operations was 155.4 + 190.3 + 269.2 + 133.6 = $749 Mil.
Revenue was 741.5 + 871.3 + 975 + 1034.5 = $3,622 Mil.
Gross Profit was 462.6 + 546.4 + 623.3 + 656.6 = $2,289 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(5391.7 + 5515.9 + 6820.7 + 6596.2 + 6264.5) / 5 = $6117.8 Mil.
Total Assets at the begining of this year (Dec22) was $5,392 Mil.
Long-Term Debt & Capital Lease Obligation was $2,573 Mil.
Total Current Assets was $4,426 Mil.
Total Current Liabilities was $1,556 Mil.
Net Income was 97.3 + 50.9 + 101.2 + 91.8 = $341 Mil.

Revenue was 628.8 + 696.2 + 769.6 + 815.2 = $2,910 Mil.
Gross Profit was 398.1 + 449.5 + 494.2 + 541.3 = $1,883 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(4933.3 + 5057 + 5217.4 + 4899.2 + 5391.7) / 5 = $5099.72 Mil.
Total Assets at the begining of last year (Dec21) was $4,933 Mil.
Long-Term Debt & Capital Lease Obligation was $1,352 Mil.
Total Current Assets was $3,669 Mil.
Total Current Liabilities was $1,839 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

DexCom's current Net Income (TTM) was 542. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

DexCom's current Cash Flow from Operations (TTM) was 749. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=541.5/5391.7
=0.10043215

ROA (Last Year)=Net Income/Total Assets (Dec21)
=341.2/4933.3
=0.06916263

DexCom's return on assets of this year was 0.10043215. DexCom's return on assets of last year was 0.06916263. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

DexCom's current Net Income (TTM) was 542. DexCom's current Cash Flow from Operations (TTM) was 749. ==> 749 > 542 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=2572.9/6117.8
=0.42055968

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=1351.9/5099.72
=0.26509299

DexCom's gearing of this year was 0.42055968. DexCom's gearing of last year was 0.26509299. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=4425.9/1556
=2.84440874

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=3668.8/1839.3
=1.99467189

DexCom's current ratio of this year was 2.84440874. DexCom's current ratio of last year was 1.99467189. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

DexCom's number of shares in issue this year was 417.1. DexCom's number of shares in issue last year was 426. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2288.9/3622.3
=0.63189134

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1883.1/2909.8
=0.64715788

DexCom's gross margin of this year was 0.63189134. DexCom's gross margin of last year was 0.64715788. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=3622.3/5391.7
=0.67182892

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=2909.8/4933.3
=0.58982831

DexCom's asset turnover of this year was 0.67182892. DexCom's asset turnover of last year was 0.58982831. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+1+0+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

DexCom has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

DexCom  (NAS:DXCM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


DexCom Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of DexCom's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


DexCom (DexCom) Business Description

Address
6340 Sequence Drive, San Diego, CA, USA, 92121
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Executives
Sadie Stern officer: Chief Human Resources Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman director
Kevin R Sayer director
Jereme M Sylvain officer: SVP, Finance & CAO 6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Jacob Steven Leach officer: SVP, Research & Development 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Nicholas Augustinos director 754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Micheal Jon Brown officer: EVP, Chief Legal Officer 6340 SEQUENCE DR, SAN DIEGO CA 92121
Steven Robert Pacelli officer: Vice President Legal Affairs 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan officer: EVP Chief Technology Officer C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan officer: EVP Operations 1023 CHERRY ROAD, MEMPHIS TN 38117
Bridgette P Heller director TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Matthew Vincent Dolan officer: * 6340 SEQUENCE DR, SAN DIEGO CA 92121
Rimma Driscoll director C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Shelly Ramasamy Selvaraj officer: SVP Information Technology 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Paul R Flynn officer: EVP, Global Revenue 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121